Physician profile
Sara Allen
NPI 1902224736
$5,402.70
in general payments reported to CMS, 2019-2025
40 companies · $20.58 in 2025
The $20.58 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $709 · 2021: $770 · 2022: $1,504 · 2023: $1,317 · 2024: $113 · 2025: $20.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,450.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $825.53 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $815.24 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.27 | 2019-2023 | Ofev, Jardiance |
| Glaxosmithkline, LLC. | $317.93 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $298.46 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $266.27 | 2019-2023 | Breztri, Farxiga |
| Amgen INC. | $252.50 | 2019-2023 | Evenity, Prolia |
| Lilly USA, LLC | $213.91 | 2019-2023 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $186.43 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $179.96 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $162.81 | 2022 | |
| Abbott Laboratories | $130.72 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $125.14 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.34 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.62 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.